<DOC>
	<DOCNO>NCT02530424</DOCNO>
	<brief_summary>This multicenter neoadjuvant trial conduct sponsorship overall trial management Fondazione Michelangelo Italy . Women diagnosis invasive unilateral non metastatic HER2-positive ER-positive breast cancer suitable neoadjuvant therapy . Patients study receive : Trastuzumab+Pertuzumab+Palbociclib+Fulvestrant ( HPPF ) Trastuzumab 8 mg/kg load dose IV , 6 mg/kg IV q.3 wks ( repeat total 6 administration ) Pertuzumab 840 mg load dose IV , 420 mg IV q . 3 wks ( repeat total 6 administration ) Palbociclib 125 mg po q.d . x 21 q . 4 wks ( = 1 cycle ; repeat total 5 cycle ) Fulvestrant give intra-muscle dose 500 mg every 4 week ( repeat 5 time ) additional 500 mg dose give two week initial dose ( total administration include additional one = 6 ) The total duration neoadjuvant palbociclib ( 5 cycle every 4 week ) fulvestrant ( 5 administration every 4 week plus additional dose give two week initial dose ) select match closely possible total duration six plan 3-weekly administration trastuzumab pertuzumab Definitive surgery perform earlier 14 day later 28 day last dose drug combination report After completion neoadjuvant surgical treatment patient receive irradiation locally acceptable . Patients also continue receive systemic drug therapy include chemotherapy , standard HER2 treatment completion full 1 year endocrine therapy accord local guideline Investigator 's discretion .</brief_summary>
	<brief_title>`` Neo-Adjuvant Treatment With Palbociclib : Effect Ki67 Apoptosis Before , During After Treatment ``</brief_title>
	<detailed_description>This multicenter neoadjuvant trial conduct sponsorship overall trial management Fondazione Michelangelo Italy . Women diagnosis invasive unilateral non metastatic HER2-positive ER-positive breast cancer suitable neoadjuvant therapy . Patients study receive : Trastuzumab+Pertuzumab+Palbociclib+Fulvestrant ( HPPF ) Trastuzumab 8 mg/kg load dose IV , 6 mg/kg IV q.3 wks ( repeat total 6 administration ) Pertuzumab 840 mg load dose IV , 420 mg IV q . 3 wks ( repeat total 6 administration ) Palbociclib 125 mg po q.d . x 21 q . 4 wks ( = 1 cycle ; repeat total 5 cycle ) Fulvestrant give intra-muscle dose 500 mg every 4 week ( repeat 5 time ) additional 500 mg dose give two week initial dose ( total administration include additional one = 6 ) The total duration neoadjuvant palbociclib ( 5 cycle every 4 week ) fulvestrant ( 5 administration every 4 week plus additional dose give two week initial dose ) select match closely possible total duration six plan 3-weekly administration trastuzumab pertuzumab Definitive surgery perform earlier 14 day later 28 day last dose drug combination report After completion neoadjuvant surgical treatment patient receive irradiation locally acceptable . Patients also continue receive systemic drug therapy include chemotherapy , standard HER2 treatment completion full 1 year endocrine therapy accord local guideline Investigator 's discretion . Primary objective : - Characterize change Ki67 baseline therapy 2 week surgery ( approximately 22 week start neoadjuvant therapy HPPF ) . - Characterize change apoptosis baseline therapy surgery ( approximately 22 week start neoadjuvant therapy HPPF ) . - Study tolerability profile combination Secondary objective : - Assess rate pathological complete response ( pCR ) define ypT0-ypTis ypN0 surgery - Define clinical objective response rate end combination - Conduct molecular clinical analysis assess presence informative marker benefit addition Ki67 apoptosis</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Female patient age 18 year old tumor suitable neoadjuvant treatment 2 . Early ( &gt; 1.5 cm ) locally advance untreated breast cancer 3 . Histologically confirm invasive unilateral breast cancer 4 . HER2positive disease centrally confirm 5 . Positive estrogen receptor ( ER ) &gt; 10 % know progesterone receptor ( PgR ) 6 . Available paraffinembedded tumor block take diagnostic biopsy central retrospective confirmation HER2 ER eligibility assessment Ki67 value apoptosis mandatory 7 . All patient must agree provide tumor tissue centralize assessment KI67 value apoptosis require timeline ( 2 week start protocol therapy surgery ) 8 . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 9 . Written inform consent participate trial ( approved Institutional Review Board/ Independent Ethics Committee ) obtain prior study specific screen procedure 10 . Willing able comply protocol 1 . Evidence bilateral invasive breast cancer metastatic disease ( M1 ) 2 . Pregnant lactating woman . 3 . Women childbearing potential unless ( 1 ) surgically sterile ( 2 ) use adequate measure contraception 4 . Previous treatment chemotherapy , hormonal therapy investigational drug type malignancy 5 . Previous extensive radiotherapy 6 . Previous investigational treatment condition within 4 week registration date 7 . Known hypersensitivity reaction one compound incorporated substance use protocol 8 . Previous concomitant malignancy type could affect compliance protocol interpretation result . 9 . Other serious illness medical condition include : history document congestive cardiac failure ; angina pectoris require antianginal medication ; evidence transmural infarction ECG ; poorly control hypertension ; clinically significant valvular heart disease ; highrisk uncontrolled arrhythmias 10 . Baseline leave ventricular ejection fraction ( LVEF ) &lt; 55 % echocardiography multigated scintigraphic scan ( MUGA ) 11 . QTc ( correct QT interval ) &gt; 480 msec family personal history long short QT syndrome , Brugada syndrome know history QTc prolongation , Torsade de Pointes ( TdP ) 12 . Patients history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant precluding inform consent adversely affect compliance study drug 13 . Serious uncontrolled infection ( bacterial viral ) poorly control diabetes mellitus 14 . Current use anticipate need food drug know strong CYP3A4 ( cytochrome P450 3A4 ) inhibitor inducers 15 . Uncontrolled electrolyte disorder compound effect QTc prolong drug ( e.g. , hypocalcemia , hypokalemia , hypomagnesemia ) 16 . Abnormal baseline hematological value : 17 . Abnormal baseline liver function , bilirubin , creatinine and/or INR ( international normalize ratio )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HER2-positive</keyword>
	<keyword>ER-positive</keyword>
	<keyword>invasive</keyword>
	<keyword>CDK4,6</keyword>
	<keyword>Palbociclib</keyword>
	<keyword>neoadjuvant treatment</keyword>
</DOC>